Cardiac Dimensions, a privately held medical device company, hired Gregory D. Casciaro as its CEO and President on Dec. 15.
Casciaro was formerly CEO and President of AccessClosure, Inc., an interventional cardiology medical device company that Cardinal Health acquired for $320 million in cash in April 2014.
He has also served as CEO and President of XTENT, Inc., Orquest, Inc. and General Surgical Innovations. All three of those companies were acquired by larger companies, according to a Cardiac Dimensions news release.
Cardiac Dimensions has developed the Carillon Mitral Contour System, a percutaneous mitral annuloplasty implantable device intended to treat functional mitral regurgitation in patients with heart failure. The system has received a CE Mark in Europe, but it is not FDA-approved.
In March, Cardiac Dimensions announced it had received $15.2 million in equity financing from two investment firms: Life Sciences Partners and Aperture Venture Partners. The total amount of financing in the round was $43 million, which the company said it would use to fund a blinded, randomized trial evaluating the Carillon system in patients with functional mitral regurgitation.
Approximately 70 percent of the 20 million people who have heart failure also have functional mitral regurgitation, according to the company.